Jennifer Jia

Jennifer Jia asked about the greatest opportunities and drivers for the double-digit IBS-C market growth, its sustainability, and how XPHOZAH is expected to reach its $750 million peak opportunity based on current trends.

Answer

CEO Mike Raab highlighted the significant IBS-C market opportunity, with 50,000 new patients monthly and 7 million annual prescriptions, emphasizing IBSRELA's clinical differentiation. For XPHOZAH, he explained the $750 million target is achievable by focusing on the Medicaid and commercial patient segments, which represent a substantial portion of the total dialysis population.

Jennifer Jia from Cantor Fitzgerald, L.P. asked about the greatest opportunities within the IBS-C market for IBSRELA, the drivers and sustainability of its double-digit market growth, and how Ardelyx plans to achieve the $750 million peak opportunity for XPHOZAH based on current trends.

Answer

CEO Mike Raab highlighted the significant IBS-C market opportunity, with 50,000 new patients monthly and 7 million annual prescriptions, requiring only a small fraction to reach the $1 billion target, driven by IBSRELA's clinical differentiation. For XPHOZAH, he explained that the $750 million peak is achievable by targeting the non-Medicare patient population (Medicaid and commercial), which represents less than 100,000 patients, given the product's strong performance in this segment.